Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy via a Cholinergic Anti-Inflammatory Pathway

Hypertension

Volumn 65, Issue 6, 2015, Pages 1238-1244

  Mao, Yuanjie ^a   Tokudome, Takeshi ^a   Kishimoto, Ichiro ^a   Otani, Kentaro ^a   Nishimura, Hirohito ^a   Yamaguchi, Osamu ^b   Otsu, Kinya ^c   Miyazato, Mikiya ^a   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cardiomegaly; ghrelin; inflammation; mice, knockout

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; GHRELIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLATROPINE; NICOTINE; ATROPINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AORTA CONSTRICTION; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR RISK; CONTROLLED STUDY; HEART FAILURE; HEART SIZE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MOUSE; NONHUMAN; PARASYMPATHETIC NERVE; PRESSURE OVERLOAD INDUCED CARDIAC HYPERTROPHY; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SUDDEN DEATH; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; CARDIOMEGALY; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE PRESSURE; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; REFERENCE VALUE;

ANALYSIS OF VARIANCE; ANIMALS; ATROPINE DERIVATIVES; CARDIOMEGALY; CHOLINERGIC AGENTS; DISEASE MODELS, ANIMAL; GHRELIN; MICE; MICE, KNOCKOUT; NICOTINE; RANDOM ALLOCATION; REFERENCE VALUES; SIGNAL TRANSDUCTION; VENTRICULAR PRESSURE;

EID: 84937604128     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04864     Document Type: Article

References (38)

1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-341. doi: 10.1067/mhj.2001.113218.
2. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res. 2004;95:1140-1153. doi: 10.1161/01.RES.0000150734.79804.92.
3. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science. 1988;242:941-944.
4. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factoralpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 1998;97:1392-1400.
5. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol. 2007;151:915-929. doi: 10.1038/sj.bjp.0707264.
6. Wilund KR, Rosenblat M, Chung HR, Volkova N, Kaplan M, Woods JA, Aviram M. Macrophages from alpha 7 nicotinic acetylcholine receptor knockout mice demonstrate increased cholesterol accumulation and decreased cellular paraoxonase expression: a possible link between the nervous system and atherosclerosis development. Biochem Biophys Res Commun. 2009;390:148-154. doi: 10.1016/j.bbrc.2009.09.088.
7. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458-462. doi: 10.1038/35013070.
8. Hofer S, Eisenbach C, Lukic IK, et al. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med. 2008;36:404-408. doi: 10.1097/01.CCM.0B013E31816208B3.
9. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, Tracey KJ, Al-Abed Y, Metz CN. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med. 2005;201:1113-1123. doi: 10.1084/jem.20040463.
10. Mabley JG, Pacher P, Southan GJ, Salzman AL, Szabó C. Nicotine reduces the incidence of type I diabetes in mice. J Pharmacol Exp Ther. 2002;300:876-881.
11. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330:811-815. doi: 10.1056/NEJM199403243301202.
12. Leib C, Göser S, Lüthje D, Öttl R, Tretter T, Lasitschka F, Zittrich S, Pfitzer G, Katus HA, Kaya Z. Role of the cholinergic antiinflammatory pathway in murine autoimmune myocarditis. Circ Res. 2011;109:130-140. doi: 10.1161/CIRCRESAHA.111.245563.
13. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853-859. doi: 10.1038/nature01321.
14. Li DJ, Evans RG, Yang ZW, Song SW, Wang P, Ma XJ, Liu C, Xi T, Su DF, Shen FM. Dysfunction of the cholinergic anti-inflammatory pathway mediates organ damage in hypertension. Hypertension. 2011;57:298-307. doi: 10.1161/HYPERTENSIONAHA.110.160077.
15. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660. doi: 10.1038/45230.
16. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988. doi: 10.1210/jcem.87.6.8739.
17. Mao Y, Tokudome T, Kishimoto I. Ghrelin as a treatment for cardiovascular diseases. Hypertension. 2014;64:450-454. doi: 10.1161/HYPERTENSIONAHA.114.03726.
18. Huda MS, Mani H, Dovey T, Halford JC, Boyland E, Daousi C, Wilding JP, Pinkney J. Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. Clin Endocrinol (Oxf). 2010;73:678-685. doi: 10.1111/j.1365-2265.2010.03865.x.
19. Sato N, Kanai S, Takano S, Kurosawa M, Funakoshi A, Miyasaka K. Central administration of ghrelin stimulates pancreatic exocrine secretion via the vagus in conscious rats. Jpn J Physiol. 2003;53:443-449.
20. Li Y, Wu X, Zhao Y, Chen S, Owyang C. Ghrelin acts on the dorsal vagal complex to stimulate pancreatic protein secretion. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1350-G1358. doi: 10.1152/ajpgi.00493.2005.
21. Shimizu S, Akiyama T, Kawada T, Sonobe T, Kamiya A, Shishido T, Tokudome T, Hosoda H, Shirai M, Kangawa K, Sugimachi M. Centrally administered ghrelin activates cardiac vagal nerve in anesthetized rabbits. Auton Neurosci. 2011;162:60-65. doi: 10.1016/j.autneu.2011.04.001.
22. Dornonville de la Cour C, Lindqvist A, Egecioglu E, Tung YC, Surve V, Ohlsson C, Jansson JO, Erlanson-Albertsson C, Dickson SL, Hakanson R. Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice. Gut. 2005;54:907-913.
23. Mao Y, Tokudome T, Otani K, Kishimoto I, Nakanishi M, Hosoda H, Miyazato M, Kangawa K. Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves. Endocrinology. 2012;153:3426-3434. doi: 10.1210/en.2012-1065.
24. Thireau J, Zhang BL, Poisson D, Babuty D. Heart rate variability in mice: a theoretical and practical guide. Exp Physiol. 2008;93:83-94. doi: 10.1113/expphysiol.2007.040733.
25. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141:122-131. doi: 10.1016/j.ijcard.2009.09.543.
26. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, Hosoda H, Kangawa K. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2008;294:H426-H432. doi: 10.1152/ajpheart.00643.2007.
27. Mao Y, Tokudome T, Otani K, Kishimoto I, Miyazato M, Kangawa K. Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice. Endocrinology. 2013;154:1854-1863. doi: 10.1210/en.2012-2132.
28. Higashikuni Y, Tanaka K, Kato M, Nureki O, Hirata Y, Nagai R, Komuro I, Sata M. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor ?B activation. J Am Heart Assoc. 2013;2:e000267. doi: 10.1161/JAHA.113.000267.
29. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225-231. doi: 10.1161/HYPERTENSIONAHA.109.148635.
30. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92:4862-4866.
31. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, ODonnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol. 2007;171:315-325. doi: 10.2353/ajpath.2007.061078.
32. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, Matsui A, Katsume A, Yamaguchi S, Nishikawa K, Isoda K, Riches DW, Matoba S, Okigaki M, Matsubara H. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res. 2009;105:1149-1158. doi: 10.1161/CIRCRESAHA.109.208199.
33. Rajan D, Wu R, Shah KG, Jacob A, Coppa GF, Wang P. Human ghrelin protects animals from renal ischemia-reperfusion injury through the vagus nerve. Surgery. 2012;151:37-47. doi: 10.1016/j.surg.2011.06.027.
34. Wu R, Dong W, Cui X, Zhou M, Simms HH, Ravikumar TS, Wang P. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg. 2007;245:480-486. doi: 10.1097/01. sla.0000251614.42290.ed.
35. Cheyuo C, Wu R, Zhou M, Jacob A, Coppa G, Wang P. Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock. 2011;35:258-265. doi: 10.1097/SHK.0b013e3181f48a37.
36. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565. doi: 10.1161/01. CIR.0000081775.72651.B6.
37. Nishiue T, Tsuji H, Tarumi N, Tokunaga S, Tamura K, Masaki M, Inada M, Iwasaka T. Heart rate variability and left ventricular dilatation early after myocardial infarction. J Electrocardiol. 1999;32:263-268.
38. Du XJ. Gender modulates cardiac phenotype development in genetically modified mice. Cardiovasc Res. 2004;63:510-519. doi: 10.1016/j. cardiores.2004.03.027.